TNONW Tenon Medical, Inc.

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001560293
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Tenon Medical is an early-stage surgical device company with promising 20.4% revenue growth and healthy 59.8% gross margins, indicating product-market fit. However, the company is burning $10.7M annually in operating cash flow against only $3.9M in revenue, with approximately 4 months of cash runway at current burn rates. Without rapid revenue acceleration, significant cost reduction, or emergency financing, the company faces severe solvency risk.

Strengths

  • + Strong gross margin of 59.8% indicates strong product value and pricing power
  • + Revenue growing 20.4% YoY demonstrates market demand for surgical devices
  • + Debt-free balance sheet with no long-term debt obligations
  • + Adequate short-term liquidity with 2.11x current ratio and 1.78x quick ratio
  • + Net loss improving 8.2% YoY shows operational efficiency gains

Risks

  • ! Severe cash burn of $10.7M annually against $3.9M revenue creates ~4 month runway with current $3.8M cash reserves
  • ! Operating margin of -324.3% indicates operating expenses 13x revenue, unsustainable even for early-stage companies
  • ! Free cash flow of -$11.0M compounds liquidity crisis and limits ability to fund operations without external capital
  • ! Negative ROE (-249.1%) and ROA (-116.7%) indicate extremely poor capital efficiency and asset utilization
  • ! High dilution risk from required future financing at distressed valuations

Key Metrics to Watch

Financial Metrics

Revenue
3.9M
Net Income
-12.6M
EPS (Diluted)
$-1.70
Free Cash Flow
-11.0M
Total Assets
10.8M
Cash
3.8M

Profitability Ratios

Gross Margin 59.8%
Operating Margin -324.3%
Net Margin -318.4%
ROE -249.1%
ROA -116.7%
FCF Margin -279.4%

Balance Sheet & Liquidity

Current Ratio
2.11x
Quick Ratio
1.78x
Debt/Equity
0.00x
Debt/Assets
53.2%
Interest Coverage
-376.24x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-17T15:51:23.173578 | Data as of: 2025-12-31 | Powered by Claude AI